Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

574 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.
Richardson PG, Perrot A, Mikhael J, Martin T, Beksac M, Spicka I, Capra M, D'Agostino M, Sonneveld P, Bisht K, Fukao T, Zhang R, Tada K, Tekle C, Macé S, Klippel Z, van de Velde H, Moreau P. Richardson PG, et al. Blood Cancer J. 2024 Nov 28;14(1):209. doi: 10.1038/s41408-024-01149-w. Blood Cancer J. 2024. PMID: 39609425 Free PMC article. Clinical Trial.
Editorial Expression of Concern: Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC. Mitsiades CS, et al. Among authors: richardson pg. Oncogene. 2024 Nov 11. doi: 10.1038/s41388-024-03217-8. Online ahead of print. Oncogene. 2024. PMID: 39528816 No abstract available.
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. Voorhees PM, et al. Among authors: richardson pg. Future Oncol. 2024 Oct 25:1-25. doi: 10.1080/14796694.2024.2408909. Online ahead of print. Future Oncol. 2024. PMID: 39452950
Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC. Hideshima T, et al. Among authors: richardson pg. Oncogene. 2024 Sep;43(40):3018. doi: 10.1038/s41388-024-03147-5. Oncogene. 2024. PMID: 39209967 No abstract available.
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.
Pawlyn C, Schjesvold FH, Cairns DA, Wei LJ, Davies F, Nadeem O, Abdulhaq H, Mateos MV, Laubach J, Weisel K, Ludwig H, Rajkumar SV, Sonneveld P, Jackson G, Morgan G, Richardson PG. Pawlyn C, et al. Among authors: richardson pg. Blood Cancer J. 2024 Aug 12;14(1):134. doi: 10.1038/s41408-024-01109-4. Blood Cancer J. 2024. PMID: 39134544 Free PMC article. Review.
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.
Liu Y, Mo CC, Hartley-Brown MA, Sperling AS, Midha S, Yee AJ, Bianchi G, Piper C, Tattersall A, Nadeem O, Laubach JP, Richardson PG. Liu Y, et al. Among authors: richardson pg. Expert Rev Hematol. 2024 Aug;17(8):445-465. doi: 10.1080/17474086.2024.2382897. Epub 2024 Jul 27. Expert Rev Hematol. 2024. PMID: 39054911 Review.
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
Kapoor P, Nathwani N, Jelinek T, Pour L, Perrot A, Dimopoulos MA, Huang SY, Spicka I, Chhabra S, Lichtman E, Mateos MV, Kanagavel D, Zhao L, Guillemin-Paveau H, Macé S, van de Velde H, Richardson PG. Kapoor P, et al. Among authors: richardson pg. Eur J Haematol. 2024 Nov;113(5):593-605. doi: 10.1111/ejh.14270. Epub 2024 Jul 12. Eur J Haematol. 2024. PMID: 38993150 Clinical Trial.
574 results